BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25684563)

  • 41. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
    Sebastiani G; Castera L; Halfon P; Pol S; Mangia A; Di Marco V; Pirisi M; Voiculescu M; Bourliere M; Alberti A
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1202-16. PubMed ID: 21981787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.
    Li YH; Yang LH; Sha KH; Liu TG; Zhang LG; Liu XX
    World J Gastroenterol; 2015 Jun; 21(22):7008-13. PubMed ID: 26078579
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.
    Lydatakis H; Hager IP; Kostadelou E; Mpousmpoulas S; Pappas S; Diamantis I
    Liver Int; 2006 Sep; 26(7):864-71. PubMed ID: 16911470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients.
    Omran MM; Farid K; Emran TM; Attallah AA
    Arab J Gastroenterol; 2011 Jun; 12(2):74-9. PubMed ID: 21684477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients.
    Anty R; Hastier A; Canivet CM; Patouraux S; Schneck AS; Ferrari-Panaia P; Ben-Amor I; Saint-Paul MC; Gugenheim J; Gual P; Iannelli A; Tran A
    Obes Surg; 2016 Sep; 26(9):2138-2143. PubMed ID: 26787197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2014 May; 60(5):1055-62. PubMed ID: 24445215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?
    Cengiz M; Candır BA; Yılmaz G; Akyol G; Ozenirler S
    World J Gastroenterol; 2013 Nov; 19(42):7412-8. PubMed ID: 24259972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.
    Harrison SA; Calanna S; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal A; Sejling AS; Newsome PN
    Contemp Clin Trials; 2020 Oct; 97():106174. PubMed ID: 33039693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
    J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The PAPAS index: a novel index for the prediction of hepatitis C-related fibrosis.
    Ozel BD; Poyrazoğlu OK; Karaman A; Karaman H; Altinkaya E; Sevinç E; Zararsiz G
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):895-900. PubMed ID: 25951491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intestinal Trefoil Factor 3 Alleviates the Intestinal Barrier Function Through Reducing the Expression of TLR4 in Rats with Nonalcoholic Steatohepatitis.
    Wang Y; Liang K; Kong W
    Arch Med Res; 2019 Jan; 50(1):2-9. PubMed ID: 31101239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis.
    Yamasaki Y; Nouso K; Miyahara K; Wada N; Dohi C; Morimoto Y; Kinugasa H; Takeuchi Y; Yasunaka T; Kuwaki K; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Iwasaki Y; Amano M; Nishimura S; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):528-34. PubMed ID: 25168691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index.
    Huwart L; Sempoux C; Salameh N; Jamart J; Annet L; Sinkus R; Peeters F; ter Beek LC; Horsmans Y; Van Beers BE
    Radiology; 2007 Nov; 245(2):458-66. PubMed ID: 17940304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.